目錄:北京索萊寶科技有限公司>>抗體>>Polyclonal Antibody>> K106617PAnti-CIP2A Polyclonal Antibody
| 供貨周期 | 現貨 | 規格 | 50ul/100ul |
|---|---|---|---|
| 貨號 | K106617P | 應用領域 | 醫療衛生,環保,化工,生物產業,農林牧漁 |
| 主要用途 | WB |
Anti-CIP2A Polyclonal Antibody
| 英文名稱 | Anti-CIP2A Polyclonal Antibody |
|---|---|
| 宿主 | Rabbit |
| 別名 | CIP2A;KIAA1524;Protein CIP2A;p90 |
| 應用 | WB |
| 稀釋比例 | WB 1:500-2000. |
| 交叉反應 | Human |
| 蛋白分子量 | 102kd |
| Gene ID | 57650 |
| 保存 | Store at -20°C. Avoid freeze / thaw cycles. |
| 儲存液 | Buffer: PBS with 0.03% Proclin300, 50% glycerol, pH7.3. |
| 純化方法 | Affinity purification |
| 亞型 | IgG |
| 免疫原 | Recombinant protein of human CIP2A |
| 性狀 | 液體 |
| Public Immunogen Range | Recombinant protein of human CIP2A |
| Subcellular Locations | Cytoplasm Cell membrane |
| Swiss Prot | Q8TCG1 |
| 克隆類型 | Polyclonal Antibody |
| 背景資料 | Cancerous inhibitor of protein phosphatase 2A (CIP2A), also designated p90 autoantigen or KIAA1524, is a single-pass membrane protein that exhibits oncogenic activity. CIP2A is known to inhibit PP2A (protein phosphatase 2A) dephosphorylation of c-Myc, thereby stabilizing c-Myc (an oncogenic transcription factor) and promoting tumor formation and malignant cell growth. PP2A is a trimeric protein complex consisting of three subunits: a scaffold subunit, a catalytic subunit and a regulatory subunit. CIP2A specifically interacts with the catalytic subunit of PP2A to inhibit its activity. Inhibition of PP2A activity is a crucial step allowing for the progression of human cell transformation. Further supporting its role as an oncoprotein, CIP2A is known to be overexpressed in colon, gastric, and head and neck squamous cell carcinomas. |
16
化工儀器網